Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis

RVL Pharmaceuticals logo

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.19
52-Week Range
N/A
Volume
63.96 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Stock News Headlines

Raval ICS Ltd.
Trump’s Back, but DC’s Coming for Your Money!
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
RVLPQ RVL Pharmaceuticals plc
RVL Pharmaceuticals PLC RVLPQ
See More Headlines

RVLP Stock Analysis - Frequently Asked Questions

RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.03. The company had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that RVL Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cardiff Oncology (CRDF), Osmotica Pharmaceuticals (OSMT), AbCellera Biologics (ABCL), Amarin (AMRN) and Coda Octopus Group (CODA).

Company Calendar

Last Earnings
3/20/2023
Today
11/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
125
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$49.72 million
Book Value
$0.51 per share

Miscellaneous

Free Float
106,504,000
Optionable
Optionable
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:RVLP) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners